₹ 7,160.93 Cr
1.82%
S&P BSE Healthcare TRI
INF204K01968
5000.0
1000.0
100
Sailesh Raj Bhan
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
Nippon India Pharma Fund-Growth Plan-Growth Option | 50.88 | 14.63 | 26.37 |
S&P BSE Healthcare TRI | 50.08 | 13.58 | 22.23 |
Equity
Debt
Others
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Company | Holdings (%) |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.37 |
Lupin Ltd. | 7.74 |
Divi's Laboratories Ltd. | 7.52 |
Cipla Ltd. | 6.26 |
Apollo Hospitals Enterprise Ltd. | 5.29 |
Dr. Reddy's Laboratories Ltd. | 4.45 |
Gland Pharma Ltd. | 4.37 |
Zydus Lifesciences Ltd. | 3.77 |
Vijaya Diagnostic Centre Ltd. | 3.59 |
JB Chemicals & Pharmaceuticals Ltd. | 3.16 |
Sector | Holdings (%) |
---|---|
Healthcare | 98.34 |
Others | 1.66 |
Scheme Name | 5Y (%) |
---|---|
Nippon India Pharma Fund Gr Gr | 26.37 |
ICICI Pru Pharma Healthcare and Diagnostics PHD Fund Cum | 27.6 |
ABSL Pharma and Healthcare Reg Gr | 0.0 |
Tata India Pharma & Healthcare Reg Gr | 25.17 |
UTI Healthcare Reg Gr | 24.81 |
Mirae Asset Healthcare Reg Gr | 27.12 |
LIC MF Healthcare Fund Reg Gr | 20.85 |
SBI HEALTHCARE Opportunities Reg Gr | 26.98 |
DSP Healthcare Reg Gr | 27.95 |
ITI Pharma and Healthcare Fund Reg Gr | 0.0 |